NASDAQ: NCNANucana PLC Stock
$3.78-0.01 (-0.26%)
Updated Apr 19, 2024
NCNA Price
$3.78
Fair Value Price
$0.40
Market Cap
$7.98M
52 Week Low
$3.40
52 Week High
$23.75
P/E
-0.22x
P/B
0.42x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$34.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.87
Operating Cash Flow
-$41M
Beta
1.03
Next Earnings
May 15, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NCNA Overview
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NCNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NCNA ($3.78) is overvalued by 849.18% relative to our estimate of its Fair Value price of $0.40 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NCNA ($3.78) is not significantly undervalued (849.18%) relative to our estimate of its Fair Value price of $0.40 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NCNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NCNA due diligence checks available for Premium users.
Be the first to know about important NCNA news, forecast changes, insider trades & much more!
NCNA News
Valuation
NCNA fair value
Fair Value of NCNA stock based on Discounted Cash Flow (DCF)
Price
$3.78
Fair Value
$0.40
Overvalued by
850.44%
NCNA ($3.78) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NCNA ($3.78) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NCNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NCNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
15.81x
Market
40.51x
NCNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.42x
Industry
5.74x
NCNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NCNA's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.7M
Profit Margin
0%
NCNA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$35.2M
Liabilities
$16.4M
Debt to equity
0.87
NCNA's short-term assets ($32.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NCNA's short-term assets ($32.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NCNA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NCNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.2M
Investing
$67.1k
Financing
-$54.4k
NCNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NCNA vs Biotech Stocks
Nucana Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.